JAK2 Inhibitor BMS-911543

Preferred Label : JAK2 Inhibitor BMS-911543;

NCIt related terms : BMS-911543;

NCIt definition : An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS-911543 selectively inhibits JAK2, thereby preventing the JAK/STAT (signal transducer and activator of transcription) signaling cascade, including activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.;

UNII : 7N03P021J8;

InChIKey : JCINBYQJBYJGDM-UHFFFAOYSA-N;

CAS number : 1271022-90-2;

Molecule name : BMS-911543; BMS 911543;

Détails

Origin ID

C95702;

UMLS CUI

C2987343;

Currated CISMeF NLP mapping
- BMS-911543 [MeSH concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- BMS-911543 [MeSH concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Tyrosine-Protein Kinase JAK2 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients